| pubmed-article:20655797 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20655797 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:20655797 | lifeskim:mentions | umls-concept:C0079189 | lld:lifeskim |
| pubmed-article:20655797 | lifeskim:mentions | umls-concept:C1425473 | lld:lifeskim |
| pubmed-article:20655797 | lifeskim:mentions | umls-concept:C1425474 | lld:lifeskim |
| pubmed-article:20655797 | lifeskim:mentions | umls-concept:C1425475 | lld:lifeskim |
| pubmed-article:20655797 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:20655797 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20655797 | pubmed:dateCreated | 2010-9-13 | lld:pubmed |
| pubmed-article:20655797 | pubmed:abstractText | IL-28A, IL-28B and IL-29 (also designated type III interferons) constitute a new subfamily within the IL-10-interferon family. They are produced by virtually any nucleated cell type, particularly dendritic cells, following viral infection or activation with bacterial components, and mediate their effects via the IL-28R1/IL-10R2 receptor complex. Although IL-28/IL-29 are closer to the IL-10-related cytokines in terms of gene structure, protein structure, and receptor usage, they display type I interferon-like anti-viral and cytostatic activities. Unlike type I interferons, the target cell populations of IL-28/IL-29 are restricted and mainly include epithelial cells and hepatocytes. These properties suggest that IL-28/IL-29 are potential therapeutic alternatives to type I interferons in terms of viral infections and tumors. This review describes the current knowledge about these cytokines. | lld:pubmed |
| pubmed-article:20655797 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20655797 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20655797 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20655797 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:20655797 | pubmed:issn | 1879-0305 | lld:pubmed |
| pubmed-article:20655797 | pubmed:author | pubmed-author:WolkKerstinK | lld:pubmed |
| pubmed-article:20655797 | pubmed:author | pubmed-author:SabatRobertR | lld:pubmed |
| pubmed-article:20655797 | pubmed:author | pubmed-author:WitteEllenE | lld:pubmed |
| pubmed-article:20655797 | pubmed:author | pubmed-author:WitteKatrinK | lld:pubmed |
| pubmed-article:20655797 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20655797 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20655797 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:20655797 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20655797 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20655797 | pubmed:pagination | 237-51 | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:meshHeading | pubmed-meshheading:20655797... | lld:pubmed |
| pubmed-article:20655797 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20655797 | pubmed:articleTitle | IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. | lld:pubmed |
| pubmed-article:20655797 | pubmed:affiliation | Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Charitéplatz 1, 10117 Berlin, Germany. | lld:pubmed |
| pubmed-article:20655797 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20655797 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:20655797 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20655797 | lld:pubmed |
